The Intercept Pharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.
What was Intercept Pharma’s price range in the past 12 months?
Intercept Pharma lowest stock price was $13.88 and its highest was $55.59 in the past 12 months.
What is Intercept Pharma’s market cap?
Intercept Pharma’s market cap is $560.44M.
What is Intercept Pharma’s price target?
The average price target for Intercept Pharma is $29.86. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $74.00 ,the lowest forecast is $16.00. The average price target represents 76.69% Increase from the current price of $16.9.
What do analysts say about Intercept Pharma?
Intercept Pharma’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
When is Intercept Pharma’s upcoming earnings report date?
Intercept Pharma’s upcoming earnings report date is Jul 29, 2021 which is in 3 days.
How were Intercept Pharma’s earnings last quarter?
Intercept Pharma released its earnings results on May 06, 2021. The company reported -$1.22 earnings per share for the quarter, beating the consensus estimate of -$1.481 by $0.261.
Is Intercept Pharma overvalued?
According to Wall Street analysts Intercept Pharma’s price is currently Undervalued.
Does Intercept Pharma pay dividends?
Intercept Pharma does not currently pay dividends.
What is Intercept Pharma’s EPS estimate?
Intercept Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Intercept Pharma have?
Intercept Pharma has 33,160,000 shares outstanding.
What happened to Intercept Pharma’s price movement after its last earnings report?
Intercept Pharma reported an EPS of -$1.22 in its last earnings report, beating expectations of -$1.481. Following the earnings report the stock price went down -9.926%.
Which hedge fund is a major shareholder of Intercept Pharma?
Among the largest hedge funds holding Intercept Pharma’s share is Maverick Capital ltd. It holds Intercept Pharma’s shares valued at 853K.